Search results
U.S. faces 'vaccine cliff' on monkeypox
Washington Post via Yahoo News· 2 years agoFederal officials this week touted the arrival of hundreds of thousands of additional monkeypox vaccine doses, heralding it as a milestone in the...
U.S. to end purchase of COVID-19 vaccines as industry pivots to commercial market
Yahoo Finance via AOL· 2 years agoVaccine makers have been working on a transition to a commercial market in the U.S. by next year, as...
The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid
Investor's Business Daily· 2 years agoPfizer, BioNTech and Moderna are working feverishly to launch new Covid boosters ahead of a fall...
Drug companies face COVID cliff in 2023 as sales set to plummet
Reuters via Yahoo Finance· 1 year agoPharmaceutical companies that made billions from the pandemic over the past two years selling...
CDC needs to emphasize 'layered protection' against COVID-19: Walensky
Yahoo Finance via AOL· 2 years agoAs the U.S. braces for a potential surge in COVID-19 cases this fall, and with a new formula for...
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
Motley Fool via Yahoo Finance· 2 months agoTwo adages capture the dilemma investors face when they consider buying a beaten-down stock: "Don't...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Barrons.com· 2 months agoBARRON'S COVER - MAIN Understanding the products from pharmaceutical companies could be the most...
23 questions for 2023
Yahoo News· 1 year agoPhoto illustration: Jack Forbes/Yahoo News; photos: Nathan Howard/Getty Images, Mandel Ngan/AFP via Getty Images, Scott Olson/Getty Images, Chet...
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Yahoo Finance via AOL· 1 year agoCompanies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in...
Will Pfizer Be a Trillion-Dollar Stock by 2035?
Motley Fool via Yahoo Finance· 3 months agoSome investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise...